L109

Lorglumide sodium salt

Name: Lorglumide sodium salt
Brand: SIGMA
Price: 152.15 USD

solid

Synonym(s):

(±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt, CR 1409

Slide 1 of 1

Select a Size

50 MG

$152.15

List Price$179.00Save 15%

Check Cart for Availability

About This Item

Empirical Formula (Hill Notation):

C₂₂H₃₁Cl₂N₂NaO₄

CAS Number:

1021868-76-7

Molecular Weight:

481.39

NACRES:

NA.32

PubChem Substance ID:

24278098

UNSPSC Code:

12352200

MDL number:

MFCD00083183

Key Documents

View All Documentation

Product Name

Lorglumide sodium salt, solid

InChI

1S/C22H32Cl2N2O4.Na/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16;/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28);/q;+1/p-1

SMILES string

[Na+].CCCCCN(CCCCC)C(=O)C(CCC([O-])=O)NC(=O)c1ccc(Cl)c(Cl)c1

InChI key

JCNPYMDDOUQTBK-UHFFFAOYSA-M

form

solid

color

white

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL
H₂O: 10 mg/mL
methanol: 28 mg/mL

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	SML2236	SML0130	L119
Sigma-Aldrich L109 Lorglumide sodium salt	Sigma-Aldrich SML2236 L-012 sodium salt	Sigma-Aldrich SML0130 Loxiglumide	Sigma-Aldrich L119 L-703,606 oxalate salt hydrate
form solid	form powder	form powder	form solid
Quality Level 100	Quality Level -	Quality Level 100	Quality Level 100
solubility 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL, methanol: 28 mg/mL, H₂O: 10 mg/mL	solubility H₂O: 2 mg/mL, clear	solubility DMSO: ≥5 mg/mL	solubility DMSO: >10 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 11 mg/mL, H₂O: slightly soluble <2 mg/mL
color white	color yellow to orange	color white to beige	color white
Gene Information human ... CCKAR(886)	Gene Information -	Gene Information -	Gene Information human ... TACR1(6869)

Application

Lorglumide sodium salt has been used as a cck-a (cholecystokinin A) receptor antagonist for peptide determination in rat islet cells.[1] It has been used as a CCK1 inhibitor to check the effect of cck1 (cck-a) and cck2 (cck-b) receptors on cerulein-induced upregulation of egr-1 (early growth response 1) expression in rat pancreatic acinar cells.[2]

Biochem/physiol Actions

Potent and selective non-peptide cholecystokinin (CCK_A) receptor antagonist; orally active.[3][4]

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The role of brain-gut peptides in the control of sodium appetite.

G L Edwards et al.

Annals of the New York Academy of Sciences, 897, 192-197 (2000-02-17)

Ingestion of food and fluid stimulates release of a number of peptides from the gastrointestinal system. These peptides are recognized to act as neurotransmitters/neuromodulators and act at both peripheral and central receptors. Many studies indicate that these peptides are important

Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse.

H W Suh et al.

Peptides, 16(7), 1229-1234 (1995-01-01)

Various doses of sulfated cholecystokinin octapeptide (CCK-8s) injected intracerebroventricularly (ICV) alone did not show any antinociceptive effect. CCK-8s (0.01-1 ng) pretreated ICV for 10 min dose-dependently attenuated the inhibition of the tail flick response induced by ICV-administered morphine (2 micrograms).

Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.

F Makovec et al.

Arzneimittel-Forschung, 37(11), 1265-1268 (1987-11-01)

Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK

Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.

M D'Amato et al.

British journal of pharmacology, 102(2), 391-395 (1991-02-01)

1. Three recently described non-peptide cholecystokinin (CCK) antagonists (devazepide, lorglumide, loxiglumide) have been studied for their antagonism of the contraction to cholecystokinin-octapeptide (CCK-OP) in human alimentary muscle and guinea-pig intestine. 2. Each antagonist caused a concentration-dependent inhibition of the contraction

Identification of N-arachidonylglycine, U18666A, and 4-androstene-3,17-dione as novel insulin Secretagogues.

Yukio Ikeda et al.

Biochemical and biophysical research communications, 333(3), 778-786 (2005-06-22)

The glucose-induced insulin secretion is fine-tuned by numerous factors. To systematically identify insulinotropic factors, we optimized a primary beta-cell-based functional assay to monitor intracellular Ca2+ flux ([Ca2+]i). By this assay system, we successfully identified several insulinotropic peptides including cholecystokinin, gastrin

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Lorglumide sodium salt